3:32 PM
 | 
Nov 10, 2017
 |  BC Extra  |  Company News

CHMP recommends basket of therapies

EMA's CHMP recommended approval of a host of therapies, including Fasenra benralizumab to treat asthma, Adynovi for hemophilia A and Prevymis letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection.

CHMP backed approval of Fasenra from AstraZeneca plc (LSE:AZN; NYSE:AZN) as an add-on maintenance treatment in adults...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >